Johnson & Johnson
Every calculator, already run for JNJ
Open the full toolkit →You have the numbers on JNJ. Get the argument.
A written report on which of these readings actually decide the outcome for Johnson & Johnson, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
23 analysts covering JNJAnalyst Price Target Disagreement for Johnson & Johnson
Wall Street's bull case implies +20% from the current price; the bear case implies -28%. A 49% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for JNJ
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through whol…
JNJ — frequently asked
Is JNJ a buy right now?
Wall Street's consensus rating on Johnson & Johnson is Buy across 23 analysts, with a mean price target of $277.91 (+5% vs. the current $265.58). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is JNJ overvalued?
JNJ trades at 30.8x trailing earnings, against a DCF fair value of $272 per share. The current price implies 6% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is JNJ's next earnings date?
Johnson & Johnson is next scheduled to report earnings around Oct 13, 2026. A full JNJ research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Johnson & Johnson?
Analysts covering Johnson & Johnson (JNJ) range from a bear-case target of $190.00 to a bull-case high of $320.00, with a mean consensus target of $277.91 across 22 analysts. The spread of $130.00 (49% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Johnson & Johnson against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Johnson & Johnson
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full JNJ research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Johnson & Johnson, in minutes. 3 free reports included with every account — no credit card required.